Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cardiac Fibrosis in Dilated Cardiomyopathy: Transcriptomics Insights, Histological Correlations, and Organoid Model Verifications [RNA-seq I]

ABSTRACT: Dilated cardiomyopathy (DCM) represents a leading cause of heart failure among younger adults. Despite endomyocardial biopsy (EMB) transcriptome enriching our understanding of DCM, the link between its gene expression and phenotype remains unclear. RNA-seq analysis of 58 DCM samples and 12 publicly available control samples unveiled about 25,000 transcripts. A principal component analysis highlighted a distinct DCM-control separation. WGCNA revealed four transcriptome modules strongly associated with DCM. The purple module, which is the DCM-related module, was enriched with fibrosis-related genes and showed FSTL3 as a pivotal DCM-associated gene.

ORGANISM(S): Homo sapiens

PROVIDER: GSE245825 | GEO | 2025/12/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Cardiac Fibrosis in Dilated Cardiomyopathy: Transcriptomics Insights, Histological Correlations, and Organoid Model Verifications [RNA-seq II]

Project description:Dilated cardiomyopathy (DCM) represents a leading cause of heart failure among younger adults. Despite endomyocardial biopsy (EMB) transcriptome enriching our understanding of DCM, the link between its gene expression and phenotype remains unclear. RNA-seq analysis of 58 DCM samples and 12 publicly available control samples unveiled about 25,000 transcripts. A principal component analysis highlighted a distinct DCM-control separation. WGCNA revealed four transcriptome modules strongly associated with DCM. The purple module, which is the DCM-related module, was enriched with fibrosis-related genes and showed FSTL3 as a pivotal DCM-associated gene. , We further validated using cardiac fibrosis organoid models. Concurrently, FSTL3 expression reflected cardiac organoid fibrosis intensity. Furthermore, FGFR1 expression, along with its phosphorylation in DCM myocardial tissue, was correlated with fibrosis severity. Cardiac fibrosis organoid models treated with AZD4547, a selective FGFR1 inhibitor, suppressed fibrosis-related markers, underscoring its potential therapeutic efficacy against DCM-related cardiac fibrosis.

2025-12-09 | GSE246298 | GEO

RNA-seq data from submiligram porcine myocardial tissue before and after myocardial infarction

Project description:We have developed an endovascular micro-endomyocardial biopsy device (Micro-EMB) with an outer diameter of 0.4 mm in order to minimize procedural risk, sampling trauma, and increase sampling specificity compared to conventional EMB. Here, we have taken micro-EMB samples from swine myocardium before, during and after myocardial infarction to detect potential gene expression responses.

2021-04-13 | GSE164962 | GEO

Cytotoxic T-cells drive out come in Inflammatory Dilated Cardiomyopathy

Project description:Dilated cardiomyopathy (DCM) is often driven by myocarditis, however, the underlying immune mechanism remains unknown. We performed bulk-RNA sequencing of endomyocardial biopsies taken 9 months (interquartile range 4-26 months) from DCM diagnosis and we found that in patients with high cardiac inflammation (at least 7 CD3+ T-cells per mm2 or at least 14 CD45+ leukocyte per mm2 endomyocardial biopsy) Perforin-1, Granzyme-A, Granzyme-H, and Interleukin-17 receptor subunit C were more often expressed compared to patients with low cardiac inflammation (less than 3 CD3+ T-cells per mm2 and less than 5 CD45+ leukocytes per mm2 endomyocardial biopsy).

2024-12-31 | GSE278521 | GEO

RNA-seq data from submiligram porcine myocardial tissue

Project description:Endomyocardial biopsy (EMB) is the gold standard for diagnosis of several heart diseases, yet its use is limited by relatively low diagnostic yield and significant complication risks. To address this, we have developed an endovascular micro-biopsy (Micro-EMB) device with an outer diameter of 0.4 mm in order to minimize procedural risk, sampling trauma, and increase sampling specificity. We have performed RNA-seq on the resulting submilligram tissue as well as controls. The gene expression signatures were compared between Micro-EMBs and conventional EMB controls, as well as negative controls such as blood and skeletal muscle.

2020-05-21 | GSE124783 | GEO

Human myocardial biopsy LC-MS/MS

Project description:In order to explore the association of the protein abundances in endomyocardial biopsies from the left and the right ventricle with echocardiographic parameters in DCM patients we did a global proteome profiling.

2020-10-20 | PXD011349 | Pride

Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy

Project description:Background: Immunoadsorption with subsequent IgG substitution (IA/IgG) represents a novel therapeutic approach in treatment of dilated cardiomyopathy (DCM) which leads to improvement of left ventricular ejection fraction (LVEF). However, response to this therapeutic intervention shows wide inter-individual variability. In this pilot study, we tested the value of clinical, biochemical and molecular parameters for prediction of the response of patients with DCM to IA/IgG. Methods & Results: Forty DCM patients underwent endomyocardial biopsies (EMBs) before IA/IgG. In 8 patients with normal LVEF (controls) EMB were obtained for clinical reasons. Clinical parameters, negative inotropic activity (NIA) of antibodies on isolated rat cardiomyocytes and gene expression profiles of EMBs were analyzed. DCM patients displaying improvement of LVEF (≥ 20% relative and ≥ 5% absolute) six month after IA/IgG were considered responders. Compared to non-responders (n=16), responders (n=24) displayed shorter disease duration (p=0.006), smaller LV internal diameter in diastole (LVIDd) (p=0.019) and stronger NIA of antibodies. Antibodies obtained from controls were devoid of NIA. Myocardial gene expression patterns were different in responders and non-responders for genes of oxidative phosphorylation, mitochondrial dysfunction, hypertrophy, and ubiquitin proteasome pathway. Integration of scores of NIA and expression levels of four genes allowed robust discrimination of responders from non-responders at baseline (sensitivity of 100 % (95% CI, 85.8%-100%); specificity up to 100% (95 % CI, 79.4%-100%, cut-off value: -0.28), and was superior to scores derived from antibodies, gene expression or clinical parameters only. Conclusion: Combined assessment of NIA of antibodies and gene expression patterns of DCM patients at baseline predicts response to IA/IgG therapy and may enable appropriate selection of patients who benefit from this therapeutic intervention.

2012-12-01 | GSE17800 | GEO

Transcription profiling of human inflammatory cardiomyopathy vs controls (DCMi) suggests novel therapeutic targets.

Project description:Since targeting of specific pathogenic pathways may be more efficient than current unspecific heart failure treatment, we obtained genomewide expression profiles of a DCM subtype characterized by cardiac inflammation (DCMi) in association with parvovirus B19. This study was entirely based on RNA isolated from endomyocardial biopsies so far only rarely used for genomic expression profiling. Experiment Overall Design: Samples derived from 8 DCMi and 4 healthy control patients were hybridised onto Affymetrix U133 Plus arrays.

2007-10-02 | E-GEOD-4172 | biostudies-arrayexpress

Gene expression profiling of human inflammatory Cardiomyopathy

2006-05-31 | GSE4172 | GEO

Endomyocardial biopsies with different acute rejection gradings

Project description:Our goals were to determine whether (i) gene expression patterns in biopsies grouped by acute rejection grade (AR) would be consistent; (ii) a characteristic gene expression profile would be associated with ISHLT Grade 0, 1A & 1B (equivalent to 1R on recently revised criteria) and ISHLT grade 3A & 3B (equivalent to 2R & 3R on recently revised criteria); (iii) gene expression patterns emerging from the analysis would provide insights into mechanisms of AR. The samples used for gene expression profiling were endomyocardial biopsies (EMB) with different acute rejection gradings. The EMB (n=2726) were obtained from the right site of the interventricular septum of heart transplant recipients (n=2423) and graded according to the guidelines of the International Society for Heart and Lung Transplantation (ISHLT, grade 0, n=9; grade1A, n=5; 1B, n=5; 3A, n=4; 3B, n=43). Selection criteria for inclusion of patients in this analysis required the availability of appropriately stored EMB samples for RNA extraction; absence of any infection that required treatment with an antimicrobial drug at anytime during the posttransplant course of the patient; absence of prior AR rejection of any grade; absence of hemodynamic compromise at the time of EMB; use of standard immunosuppressive regimen; and the absence of HLA antibodies prior to transplant.

2008-10-18 | GSE9377 | GEO

The mechanism of FSTL3 in the progression of colon cancer

Project description:FSTL3 is a multifunctional protein, and its role in cancer has attracted considerable attention. Firstly, overexpression of FSTL3 has been found to be closely associated with the occurrence and development of various tumors. The expression levels of FSTL3 are significantly elevated, which is linked to its role in promoting tumor cell proliferation, migration, and invasion. Additionally, the expression levels of FSTL3 are associated with the grading and prognosis of tumors, where high expression of FSTL3 is often correlated with the malignancy and adverse prognosis of tumors. Therefore, this study primarily explores the mechanisms by which FSTL3, acting as an exosomal cytokine, promotes the progression of colon cancer.

2025-07-31 | GSE253699 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data